JP7555156B2 - 新規ｐｌｋ１分解誘導化合物 - Google Patents

新規ｐｌｋ１分解誘導化合物 Download PDF

Info

Publication number
JP7555156B2
JP7555156B2 JP2023514160A JP2023514160A JP7555156B2 JP 7555156 B2 JP7555156 B2 JP 7555156B2 JP 2023514160 A JP2023514160 A JP 2023514160A JP 2023514160 A JP2023514160 A JP 2023514160A JP 7555156 B2 JP7555156 B2 JP 7555156B2
Authority
JP
Japan
Prior art keywords
mmol
mixture
methyl
cancer
μmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023514160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540729A (ja
Inventor
リュ，スーヒー
ミン，インスク
リ，ハンキョ
キム，ソンフン
リュ，ヒェグク
カン，クムヤン
キム，サンヨン
チュン，ソヒョン
リ，ジョンキョ
リ，ギッブム
Original Assignee
オップテラ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オップテラ インコーポレイテッド filed Critical オップテラ インコーポレイテッド
Publication of JP2023540729A publication Critical patent/JP2023540729A/ja
Application granted granted Critical
Publication of JP7555156B2 publication Critical patent/JP7555156B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023514160A 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物 Active JP7555156B2 (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
KR20210105358 2021-08-10
KR10-2021-0105358 2021-08-10
KR10-2021-0106488 2021-08-12
KR20210106488 2021-08-12
KR10-2021-0117389 2021-09-03
KR20210117389 2021-09-03
KR10-2021-0126757 2021-09-24
KR20210126757 2021-09-24
KR20220008456 2022-01-20
KR10-2022-0008456 2022-01-20
KR20220020996 2022-02-17
KR10-2022-0020996 2022-02-17
KR10-2022-0054880 2022-05-03
KR20220054880 2022-05-03
KR20220075838 2022-06-21
KR10-2022-0075838 2022-06-21
PCT/KR2022/011963 WO2023018238A1 (en) 2021-08-10 2022-08-10 Novel plk1 degradation inducing compound

Publications (2)

Publication Number Publication Date
JP2023540729A JP2023540729A (ja) 2023-09-26
JP7555156B2 true JP7555156B2 (ja) 2024-09-24

Family

ID=85200656

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2023514160A Active JP7555156B2 (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物
JP2024507883A Pending JP2024530495A (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物
JP2023514149A Active JP7555155B2 (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物
JP2024507884A Pending JP2024530195A (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2024507883A Pending JP2024530495A (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物
JP2023514149A Active JP7555155B2 (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物
JP2024507884A Pending JP2024530195A (ja) 2021-08-10 2022-08-10 新規ｐｌｋ１分解誘導化合物

Country Status (15)

Country Link
US (4) US11939334B2 (https=)
EP (4) EP4157849A4 (https=)
JP (4) JP7555156B2 (https=)
KR (5) KR102604803B1 (https=)
CN (2) CN116322700B (https=)
AU (1) AU2022327025A1 (https=)
CA (1) CA3228601A1 (https=)
CL (1) CL2024000373A1 (https=)
CO (1) CO2024001256A2 (https=)
CR (1) CR20240120A (https=)
EC (1) ECSP24010109A (https=)
IL (1) IL310678A (https=)
MX (1) MX2024001774A (https=)
PE (1) PE20240894A1 (https=)
WO (5) WO2023018236A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025530757A (ja) * 2023-02-02 2025-09-17 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
UY39892A (es) 2021-08-10 2023-03-31 Novartis Pharma Ag Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING
CN120603831A (zh) * 2022-11-29 2025-09-05 厄普特拉株式会社 具有增加的刚性的plk1降解诱导化合物
WO2024188209A1 (zh) * 2023-03-10 2024-09-19 标新生物医药科技(上海)有限公司 新颖的e3泛素连接酶配体、蛋白降解剂及其应用
KR20260022390A (ko) 2023-06-08 2026-02-19 누릭스 테라퓨틱스 인코포레이티드 Smarca2의 선택적 분해제로서의 이작용성 아진 접합체 및 이의 치료적 용도
CN121816348A (zh) 2023-08-11 2026-04-07 深圳众格生物科技有限公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
CN117126133A (zh) * 2023-08-14 2023-11-28 中国海洋大学 一种化合物及其用途
WO2025062330A1 (en) 2023-09-20 2025-03-27 Aurigene Oncology Limited Heterocyclic compounds as cbp selective degraders
WO2025125575A1 (en) 2023-12-14 2025-06-19 Astrazeneca Ab Irak4 protacs
WO2025239662A1 (ko) * 2024-05-13 2025-11-20 (주) 업테라 분해 약물-항체 접합체용 plk1 분해 유도 화합물
CN118724841A (zh) * 2024-06-14 2024-10-01 南通华祥医药科技有限公司 一种n-氨基哌啶二盐酸盐的制备方法
WO2026013577A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Piperidine-2, 6-dione derivatives useful for the targeted degradation of vav1
WO2026013576A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Dihydrouracil derivatives useful for the targeted degradation of vav1
WO2026026773A1 (zh) * 2024-07-29 2026-02-05 杭州胶联生物医药科技有限公司 作为vav1蛋白靶点降解剂的新型取代杂环类化合物
WO2026041138A1 (zh) * 2024-08-22 2026-02-26 武汉人福创新药物研发中心有限公司 作为vav1降解剂的苯并杂环类化合物及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542613A (ja) 2006-07-06 2009-12-03 アストラゼネカ アクチボラグ 新規化合物
JP2010521514A (ja) 2007-03-22 2010-06-24 エフ．ホフマン−ラ ロシュ アーゲー Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン
CN106543185A (zh) 2016-11-10 2017-03-29 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
CN109879877A (zh) 2019-03-04 2019-06-14 吉林大学 一种可降解plk1和brd4蛋白的化合物及其应用
WO2021053495A1 (en) 2019-09-16 2021-03-25 Novartis Ag Bifunctional degraders and their methods of use
WO2021061894A1 (en) 2019-09-27 2021-04-01 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2649324A1 (en) * 2006-04-12 2007-10-25 Jean-Damien Charrier Tetrahydropteridines useful as inhibitors of protein kinases
JP2011527667A (ja) 2008-06-18 2011-11-04 武田薬品工業株式会社 ハロ置換ピリミドジアゼピン
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
AU2016349781A1 (en) * 2015-11-02 2018-05-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
BR112019015484A2 (pt) * 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
CN106977584B (zh) 2017-04-19 2019-12-06 吉林大学 靶向泛素化降解plk1和brd4蛋白的化合物及其应用
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542613A (ja) 2006-07-06 2009-12-03 アストラゼネカ アクチボラグ 新規化合物
JP2010521514A (ja) 2007-03-22 2010-06-24 エフ．ホフマン−ラ ロシュ アーゲー Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン
CN106543185A (zh) 2016-11-10 2017-03-29 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
CN109879877A (zh) 2019-03-04 2019-06-14 吉林大学 一种可降解plk1和brd4蛋白的化合物及其应用
WO2021053495A1 (en) 2019-09-16 2021-03-25 Novartis Ag Bifunctional degraders and their methods of use
WO2021061894A1 (en) 2019-09-27 2021-04-01 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025530757A (ja) * 2023-02-02 2025-09-17 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物

Also Published As

Publication number Publication date
KR20230024302A (ko) 2023-02-20
CR20240120A (es) 2024-05-22
CN116261458B (zh) 2024-05-24
CO2024001256A2 (es) 2024-03-18
KR102604802B1 (ko) 2023-11-22
WO2023018238A1 (en) 2023-02-16
EP4384520A4 (en) 2025-09-03
MX2024001774A (es) 2024-04-24
US20230219966A1 (en) 2023-07-13
EP4157849A4 (en) 2024-12-11
EP4157850A1 (en) 2023-04-05
KR20230024267A (ko) 2023-02-20
KR20230024250A (ko) 2023-02-20
KR102604801B1 (ko) 2023-11-22
EP4384520A1 (en) 2024-06-19
ECSP24010109A (es) 2024-05-31
PE20240894A1 (es) 2024-04-24
KR102662205B1 (ko) 2024-04-30
EP4384521A1 (en) 2024-06-19
CN116322700B (zh) 2024-08-20
CA3228601A1 (en) 2023-02-16
US20250101025A1 (en) 2025-03-27
CN116322700A (zh) 2023-06-23
WO2023017442A1 (en) 2023-02-16
KR20240060721A (ko) 2024-05-08
JP2024530495A (ja) 2024-08-21
US11912710B2 (en) 2024-02-27
WO2023018237A1 (en) 2023-02-16
JP7555155B2 (ja) 2024-09-24
JP2023540728A (ja) 2023-09-26
US20250114460A1 (en) 2025-04-10
EP4384521A4 (en) 2025-09-03
JP2023540729A (ja) 2023-09-26
CL2024000373A1 (es) 2024-07-19
EP4157850A4 (en) 2024-11-20
KR20230024251A (ko) 2023-02-20
CN116261458A (zh) 2023-06-13
US20230242541A1 (en) 2023-08-03
WO2023018236A1 (en) 2023-02-16
KR102604803B1 (ko) 2023-11-22
EP4157849A1 (en) 2023-04-05
AU2022327025A1 (en) 2024-03-21
US11939334B2 (en) 2024-03-26
IL310678A (en) 2024-04-01
JP2024530195A (ja) 2024-08-16
WO2023017446A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
JP7555156B2 (ja) 新規ｐｌｋ１分解誘導化合物
JP7440940B2 (ja) Ｐｌｋ１の選択的分解誘導化合物
JP7820584B2 (ja) インターロイキン－１受容体関連キナーゼの二官能性分解剤及びその治療的使用
IL293961A (en) Compounds and methods for targeted degradation of androgen receptor
JP2018507877A (ja) ＣＤＫ阻害剤としてのピラゾロ［１，５−ａ］［１，３，５］トリアジンとピラゾロ［１，５−ａ］ピリミジン誘導体
AU2013272701A1 (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
TW202122382A (zh) 乙內醯脲衍生物
WO2024078581A1 (en) Selective bcl-xl protac compounds and uses thereof
AU2023250757B2 (en) Heteroaryl derivative and use thereof
CN117794936A (zh) 新型plk1降解诱导化合物
CA3213823A1 (en) Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
JP2024516194A (ja) Ｐｄ１／ｐｄ－ｌ１阻害剤としての化合物及びその方法
JP2025530757A (ja) 新規ｐｌｋ１分解誘導化合物
JP2026509069A (ja) ２，４－ジアニリノピリミジンベースのオーロラａキナーゼ選択的分解誘導化合物
KR20250105638A (ko) 경직성이 증가된 plk1 분해 유도 화합물

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240220

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20240424

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240903

R150 Certificate of patent or registration of utility model

Ref document number: 7555156

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150